CYCLOPHOSPHAMIDE INDUCES DIFFERENTIATION OF Th17 CELLS IN CANCER PATIENTS

1.  Authors:
   Nathalie Chaput and Laurence Zitvogel, Centre d'Investigation Clinique Biothérapie 507, Institut de Cancérologie Gustave Roussy, 114 rue Edouard Vaillant, 94805 Villejuif, France.PHONE: 33142116616; Fax: 33142116094. E-MAIL: chaput@igr.fr, zitvogel@igr.fr

Abstract

Low doses of the alkylating agent cyclophosphamide (CTX) mediate antiangiogenic and immunostimulatory effects, leading to potent tumoricidal activity in association with various immunotherapeutic strategies. Here, we show in rodents and cancer patients that CTX markedly promotes the differentiation of CD4⁺ T helper 17 (Th17) cells that can be recovered in both blood and tumor beds. However, CTX does not convert regulatory T cells into Th17 cells. Because Th17 are potent inducers of tissue inflammation and autoimmunity, these results suggest impact ON the clinical management of various types of malignancies treated with alkylating agents and a potential need to optimize CTX-based immunotherapy in patients. Cancer Res; 71(3); 661–5. ©2010 AACR.




© kanker gezond(er) benaderen 2015.